Details

Autor(en) / Beteiligte

• Wu, Yizhe
• Zhou, Xinglu
• Jin, Tingting
• Jin, Xinxin

Titel

1106 HZ-S506, a selective and orally bioavailable HPK1 degrader, is efficacious as a single agent or in combination with PD-1 antibody

Ist Teil von

• Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A1149-A1149

Ort / Verlag

London: BMJ Publishing Group LTD

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• BackgroundHematopoietic Progenitor Kinase 1 (HPK1/MAP4K1) has been demonstrated to restrain T cell activation through phosphorylation of SLP-76 at Serine 376 leading to TCR signal blocking. The negative feedback role of HPK1 in TCR signaling makes it a promising target for immunooncology therapy. Several HPK1 inhibitors have entered into phase 1 clinical trial. However, the HPK1 selectivity against other MAP4Ks family protein is still challenging, which may lead to the weakening of HPK1-targeted therapy. Recently, PROteolysis TArgeting Chimera (PROTAC) is a bifunctional molecule that can bring the target protein and E3 enzyme closer for ubiquitination labeling, and the target protein can be degraded by UPS system. Therefore, in theory, it can reduce the generation of drug resistance and avoid the problem of off target inhibition to further enhance subtype selectivity.MethodsHZ-S506 was discovered based on our team’s unique DaTProD® platform. Western blot and HPK1 biochemical assay were used to analyze HPK1 degradation and inhibition. T cell activation and SLP-76 phosphorylation were also conducted. The in-vivo anti-tumor efficacy was assessed in C57BL/c mice which were engrafted with CT-26 cell line.ResultsWe found that HZ-S506 potently inhibited HPK1 kinase activity (IC50 = 4.6 nM) under Km concentration of ATP, and it also had good selectivity against other MAP4K family members. HZ-S506 catalyzed the degradation of HPK1 in Jurkat and PBMC (DC50 < 10 nM). HZ-S506 treatment of jurkat T cell demonstrated robust HPK1 degradation without significant downregulation of other off-target proteins in the proteomics experiment. HZ-S506 had stimulatory effect on immune response by increasing in IL-2 production (EC50 =279.1nM) in Jurkat cell with stimulation with anti-CD3 and anti-CD28, which was more significantly more potent. Treatment with HZ-S506 also can overcome PGE2 mediated immune-suppression. Interestingly, HZ-S506 possessed excellent pharmacokinetic properties, the exposure of which is higher than its parent inhibitor (~2 folds). In efficacy studies, HZ-S506 exhibited anti-tumor activity CT26 tumor model as single agent and in combination with an anti-PD1 antibody, demonstrated robust anti-tumor activities of anti-PD1 efficacy in 4T1 and MC38 syngeneic tumor models.ConclusionsIn summary, HZ-S506 is a potent and selective degrader of HPK1 with good ADME properties and efficacy. These results support further development of HZ-S506 as a single-agent or combinational therapy with the current checkpoint inhibitors.AcknowledgementsProf. Xiaowu Dong (Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, P. R. China)Ethics ApprovalAll animal studies were performed in strict accordance with the institutional guidelines as defined by the Institutional Animal Care and Use Committee (IACUC), approved by the Animal Care and Use Committee, Zhejiang University Laboratory Animal Center (Hangzhou, China), approval ID: 20210068. All participants gave informed consent before taking part.